Literature DB >> 33353543

Gestational lipid profile as an early marker of metabolic syndrome in later life: a population-based prospective cohort study.

Maria C Adank1,2, Laura Benschop1,2, Sophia P van Streun1,2, Anna M Smak Gregoor1,2, Monique T Mulder3, Eric A P Steegers1, Sarah Schalekamp-Timmermans1,2, Jeanine E Roeters van Lennep4.   

Abstract

BACKGROUND: In pregnancy lipid levels increase with gestation resembling an atherogenic lipid profile. Currently it is unclear whether gestational lipid levels are associated with an adverse cardiovascular risk profile later in life. The aim of this study is to assess the association between gestational lipid levels and lipid levels and prevalence of the metabolic syndrome (MS) six years after pregnancy.
METHODS: In plasma of 3510 women from the Generation R Study; a prospective population-based cohort, we measured lipid levels (total cholesterol, triglycerides and high-density lipoprotein cholesterol [HDL-c]), and low-density lipoprotein cholesterol (LDL-c), remnant cholesterol and non-HDL-c were calculated in early pregnancy (median 13.2 weeks, 90% range [10.5 to 17.1]) and six years after pregnancy (median 6.5 years, 90% range [6.2 to 7.8]). MS was assessed six years after pregnancy according to the NCEP/ATP3 criteria. We also examined the influence of pregnancy complications on these associations.
RESULTS: Gestational lipid levels were positively associated with corresponding lipid levels six years after pregnancy, independent of pregnancy complications. Six years after pregnancy the prevalence of MS was 10.0%; the prevalence was higher for women with a previous placental syndrome (13.5%). Gestational triglycerides and remnant cholesterol in the highest quartile and HDL-c in the lowest quartile were associated with the highest risk for future MS, independent of smoking and body mass index.
CONCLUSIONS: Gestational lipid levels provide an insight in the future cardiovascular risk profile of women in later life. Monitoring and lifestyle intervention could be indicated in women with an unfavorable gestational lipid profile to optimize timely cardiovascular risk prevention.

Entities:  

Keywords:  Cholesterol, LDL; Lipoproteins, HDL; Metabolic syndrome; Placental syndrome; Pregnancy; Triglycerides

Year:  2020        PMID: 33353543      PMCID: PMC7756942          DOI: 10.1186/s12916-020-01868-4

Source DB:  PubMed          Journal:  BMC Med        ISSN: 1741-7015            Impact factor:   8.775


  39 in total

Review 1.  Pregnancy complications and maternal cardiovascular risk: opportunities for intervention and screening?

Authors:  Naveed Sattar; Ian A Greer
Journal:  BMJ       Date:  2002-07-20

2.  Long-term prognosis of hypertension in pregnancy.

Authors:  R Marín; M Gorostidi; C G Portal; M Sánchez; E Sánchez; J Alvarez
Journal:  Hypertens Pregnancy       Date:  2000       Impact factor: 2.108

3.  The remote prognosis of eclamptic women. Sixth periodic report.

Authors:  L C Chesley; J E Annitto; R A Cosgrove
Journal:  Am J Obstet Gynecol       Date:  1976-03-01       Impact factor: 8.661

4.  Hypertensive diseases of pregnancy and risk of hypertension and stroke in later life: results from cohort study.

Authors:  Brenda J Wilson; M Stuart Watson; Gordon J Prescott; Sarah Sunderland; Doris M Campbell; Philip Hannaford; W Cairns S Smith
Journal:  BMJ       Date:  2003-04-19

5.  Hypertensive disorders of pregnancy: a strong risk factor for subsequent hypertension 5 years after delivery.

Authors:  Asako Mito; Naoko Arata; Dongmei Qiu; Naoko Sakamoto; Atsuko Murashima; Atsuhiro Ichihara; Ryu Matsuoka; Akihiko Sekizawa; Yukihiro Ohya; Michihiro Kitagawa
Journal:  Hypertens Res       Date:  2017-11-02       Impact factor: 3.872

Review 6.  Pre-eclampsia and risk of cardiovascular disease and cancer in later life: systematic review and meta-analysis.

Authors:  Leanne Bellamy; Juan-Pablo Casas; Aroon D Hingorani; David J Williams
Journal:  BMJ       Date:  2007-11-01

7.  Prediction of later hypertension following a hypertensive pregnancy.

Authors:  A Svensson; B Andersch; L Hansson
Journal:  J Hypertens Suppl       Date:  1983-12

8.  Metabolic syndrome and pre-eclampsia.

Authors:  M C E Hooijschuur; C Ghossein-Doha; A A Kroon; P W De Leeuw; A A M Zandbergen; S M J Van Kuijk; M E A Spaanderman
Journal:  Ultrasound Obstet Gynecol       Date:  2019-07       Impact factor: 7.299

Review 9.  Pregnancy: a stress test for life.

Authors:  David Williams
Journal:  Curr Opin Obstet Gynecol       Date:  2003-12       Impact factor: 1.927

10.  Hypertensive disorders of pregnancy and subsequent maternal cardiovascular health.

Authors:  Nienke E Bergen; Sarah Schalekamp-Timmermans; Jolien Roos-Hesselink; Jeanine E Roeters van Lennep; Vincent V W Jaddoe; Eric A P Steegers
Journal:  Eur J Epidemiol       Date:  2018-05-19       Impact factor: 8.082

View more
  4 in total

Review 1.  Dyslipidemia Management in Pregnancy: Why Is It not Covered in the Guidelines?

Authors:  Joanna Lewek; Maciej Banach
Journal:  Curr Atheroscler Rep       Date:  2022-04-30       Impact factor: 5.967

2.  Comparison of global definitions of metabolic syndrome in early pregnancy among the Rajarata Pregnancy Cohort participants in Sri Lanka.

Authors:  Imasha Upulini Jayasinghe; Thilini Chanchala Agampodi; Ajith Kumara Dissanayake; Shalka Madushan Srimantha; Suneth Buddhika Agampodi
Journal:  Sci Rep       Date:  2022-02-07       Impact factor: 4.379

3.  Maternal lipid levels in early pregnancy as a predictor of childhood lipid levels: a prospective cohort study.

Authors:  Maria C Adank; Anja K Johansen; Laura Benschop; Sophia P Van Streun; Anna M Smak Gregoor; Linn K L Øyri; Monique T Mulder; Eric A P Steegers; Kirsten B Holven; Jeanine E Roeters van Lennep
Journal:  BMC Pregnancy Childbirth       Date:  2022-07-23       Impact factor: 3.105

4.  Maternal lipid profile during early pregnancy and birth weight: A retrospective study.

Authors:  Si-Meng Zhu; Han-Qiu Zhang; Cheng Li; Chen Zhang; Jia-Le Yu; Yan-Ting Wu; He-Feng Huang
Journal:  Front Endocrinol (Lausanne)       Date:  2022-09-15       Impact factor: 6.055

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.